REGN Regeneron Pharmaceuticals, Inc.
REGN Regeneron Pharmaceuticals, Inc.
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 2 scans as of 2026-10-16 2 bull converging
POC $754.74 · VWAP $717.43 · +10.2% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster EVP, Director sold $2.3M, Sep 3
Coverage
2 watchlists
REGN Price Structure
Loading timeframes…
Peers
Every watchlist REGN belongs to, members best 30-day change first — REGN highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@ibb
@biotech-scan
Reported the quarter ending 2026-06-30: revenue $4.29B, diluted EPS $12.23, net income $1.30B (SEC filing). Across the print the stock moved +9.7% (close before → first close after).
full note →Against street estimates
How REGN's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about REGN from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 1 day ago · Oct 16
- regeneron pharmaceuticals, inc.
- Regeneron Pharmaceuticals, Inc. (REGN) Q2 FY2026 earnings call transcript
- Regeneron Pharmaceuticals (REGN) Stock Price & Overview
- Regeneron Reports Second Quarter 2026 Financial and Operating Results
- Regeneron Pharmaceuticals, Inc. (REGN) stock price, news, quote and history - Yahoo Finance
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
REGN research tape
71 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.